BioSpace News Archive

Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE) today announced that the Company will host a conference call and live audio webcast on Tuesday, February 28, 2023 at 5:00 PM ET to report its fourth quarter and full year 2022 financial results and provide a corporate update.

Akari Therapeutics, Plc (Nasdaq: AKTX) today announced the Phase 3 clinical trial of nomacopan in pediatric patients with hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) is moving into Part B sooner than expected and the company is beginning the planning and design for the pivotal study in pediatric patients over 2 years of age.

Ocuphire Pharma, Inc. (Nasdaq: OCUP) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Nyxol® (phentolamine ophthalmic solution 0.75%) for the treatment of pharmacologically-induced mydriasis (RM).

Amarin Corporation plc announced that members of its Board of Directors and management team will host a live webcast on Tuesday, February 14, 2023, from 8:00 a.m. - 9:00 a.m. ET.

Novavax, Inc. (Nasdaq: NVAX) today announced a modification to its existing agreement with the U.S. Department of Health and Human Services (HHS), in collaboration with the Department of Defense, to deliver up to 1.5 million doses of the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373).

Establishment Labs Holdings Inc. (NASDAQ: ESTA) plans to announce its financial results for the quarter ended December 31, 2022, after the market closes on Monday, February 27, 2023, and will host a conference call at 4:30 pm ET that day to discuss those results.

Panbela Therapeutics, Inc. announced that, primarily as a result of the January 30, 2023 closing of its public offering of approximately $15 million of common stock and warrants, Panbela has regained compliance with applicable listing standards of The Nasdaq Stock Market.

Paris, February 13, 2023. Sanofi announced that Dr. John Reed, its Global Head of R&D, will be leaving the company to pursue a new opportunity outside Sanofi.

Anavasi Diagnostics, an NIH/RADx funded medical technology company developing novel molecular diagnostic testing for the point-of-care (POC) market, announced the Food and Drug Administration has issued an Emergency Use Authorization (EUA) for The AscencioDx® COVID-19 Test and The AscencioDx® Molecular Detector.

Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, today announced an agreement designed to expand patient access to Cleveland Diagnostics’ novel prostate cancer test, IsoPSA.